Second, although NRG1 fusions are found in multiple tumor types, zenocutuzumab has only received FDA approval for NSCLC and pancreatic adenocarcinoma, unlike tumor-agnostic agents such as larotrectinib and entrectinib (for NTRK fusion-positive tumors) or selpercatinib (for RET fusion-positive tumors). Here, RET is linked to neoplasm.